Philip S. Watson

Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease.

Philip S. Watson, D. Turner, 2016, Vaccine.

Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease.

Philip S. Watson, L. Friedland, Patricia Novy, 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Optimizing the timing of 4CMenB vaccination in adolescents and young adults based on immune persistence and booster response data

Philip S. Watson, R. Bekkat-Berkani, A. Banzhoff, 2019, Expert review of vaccines.

Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide.

R. Rappuoli, D. Medini, M. Gorla, 2019, Vaccine.

Meningococcal-group B (MenB) vaccine series completion and adherence to dosing schedule in the United States: A retrospective analysis by vaccine and payer type.

C. Hogea, D. Irwin, E. Packnett, 2019, Vaccine.

Letter to Editor.

Philip S. Watson, L. Friedland, 2019, Vaccine.